Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Plos One|December 6, 2011
Screening of peptide libraries against protective antigen of Bacillus anthracis in a disposable microfluidic cartridgeJoshua M Kogot, Yanting Zhang, Stephen J Moore, et al.
Frontiers in Microbiology|January 19, 2016
CD4+ T Cells Targeting Dominant and Cryptic Epitopes from Bacillus anthracis Lethal FactorStephanie Ascough, Rebecca J Ingram, Karen K Y Chu, et al.
Chemical Science|March 19, 2019
Fluorinated synthetic anion carriers: experimental and computational insights into transmembrane chloride transportMichael J Spooner, Hongyu Li, Igor Marques, et al.
Biorxiv : the Preprint Server for Biology|July 17, 2026
Cell-type-specific ATF6α programs regulate epithelial mitochondrial homeostasis and pericyte remodeling during physiological and exposure-accelerated lung agingXuejian Huang, Jonathan E Bard, Bat-Ider Tumenbayar, et al.
Vaccines|October 27, 2022
Impact of HLA Polymorphism on the Immune Response to Bacillus Anthracis Protective Antigen in Vaccination versus Natural InfectionStephanie Ascough, Rebecca J Ingram, Karen K Y Chu, et al.
Cancer Research|September 16, 2022
A Probody T Cell-Engaging Bispecific Antibody Targeting EGFR and CD3 Inhibits Colon Cancer Growth with Limited ToxicityLeila M Boustany, Sherry L LaPorte, Laurie Wong, et al.
Plos Pathogens|May 3, 2014
Anthrax lethal factor as an immune target in humans and transgenic mice and the impact of HLA polymorphism on CD4+ T cell immunityStephanie Ascough, Rebecca J Ingram, Karen K Chu, et al.
Science Translational Medicine|October 18, 2013
Tumor-specific activation of an EGFR-targeting probody enhances therapeutic indexLuc R Desnoyers, Olga Vasiljeva, Jennifer H Richardson, et al.
Molecular Cancer Therapeutics|June 6, 2022
Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody-Drug ConjugateShweta Singh, Laura Serwer, Amy DuPage, et al.
Pageof 2